The Technical Analyst
Franklin Genomic [HELX]
Exchange: ETF
Franklin Genomic Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.71% $30.58
America/New_York / 1 mai 2024 @ 14:02
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 9.99 mill |
| EPS: | 1.532 |
| P/E: | 19.96 |
| Earnings Date: | N/A |
| SharesOutstanding: | 0.327 mill |
| Avg Daily Volume: | 0.0009 mill |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 19.96 | sector: PE -6.11 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE 19.96 | industry: PE -6.11 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 30.28 - 30.88 ( +/- 0.99%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2006-07-03 | Transier William L | Buy | 1 843 | Common Stock |
| 2006-07-03 | Duroc-danner Bernard J | Buy | 1 340 | Common Stock |
| 2006-05-25 | Ferron Martin R | Buy | 5 655 | Common Stock |
| 2006-05-25 | Ferron Martin R | Sell | 5 655 | Stock Option (Option to Buy) |
| 2006-04-05 | Tripodo Anthony | Sell | 15 000 | Call (Option to Buy) |
| INSIDER POWER |
|---|
| 0.00 |
| Last 36 transactions |
| Buy: 118 863 | Sell: 321 554 |
Forecast:
15:42 - $30.21
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $30.58 (1.71% ) |
| Volume | 0.0003 mill |
| Avg. Vol. | 0.0009 mill |
| % of Avg. Vol | 34.22 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For HELX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
HELX
Under normal market conditions, the fund invests at least 80% of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. The fund invests predominantly in common stock. Although it may invest across economic sectors, the fund concentrates its investments in health care related industries. It is non-diversified.
Latest News
2023-01-11 18:09:00 - Seeking Alpha
Can Health Care Stocks Outperform Again In 2023?
How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.
2022-08-27 04:45:00 - Seeking Alpha
Why Now Could Be The Time To Consider Neuroscience Investments
Recognition that aging populations will give rise to new healthcare needs and heightened awareness of mental health issues are bringing renewed focus to neurological health. Recent advances in genomics and immunology, new diagnostics and surgeries, and reductions in stigma associated with mental health are unlocking radical progress in neuroscience this decade akin to the genomics revolution of the past two decades.
2022-06-10 11:21:00 - ETF Trends
Hop on HELX for Potential Biotech M&A
Blame inflation and rising interest rates, among other factors, but biotechnology mergers and acquisitions activity remains lethargic. That's despite a slump in biotech stocks dating back to early 2021 that is depressing share prices of potential targets.
2022-04-18 20:35:50 - ETF Trends
Invest in the Fully Mapped Human Genome With This ETF
Scientists have completed mapping the human genome. New research from the Telomere-to-Telomere (T2T) Consortium, a loose collaborative of about 100 scientists, shows that the team has completed a challenging 8% of the human genome left unresolved by the initial Human Genome Project.
2020-09-10 08:00:51 - seekingalpha.com
ETF Deathwatch For August 2020
Twenty-six exchange-traded products were added to the list, and 40 funds were removed, making August a busier month in terms of removals.